Original Article | Published:

Genetic background influences susceptibility to chemotherapy-induced hematotoxicity

The Pharmacogenomics Journal volume 18, pages 319330 (2018) | Download Citation

Abstract

Hematotoxicity is a life-threatening side effect of many chemotherapy regimens. Although clinical factors influence patient responses, genetic factors may also play an important role. We sought to identify genomic loci that influence chemotherapy-induced hematotoxicity by dosing Diversity Outbred mice with one of three chemotherapy drugs; doxorubicin, cyclophosphamide or docetaxel. We observed that each drug had a distinct effect on both the changes in blood cell subpopulations and the underlying genetic architecture of hematotoxicity. For doxorubicin, we mapped the change in cell counts before and after dosing and found that alleles of ATP-binding cassette B1B (Abcb1b) on chromosome 5 influence all cell populations. For cyclophosphamide and docetaxel, we found that each cell population was influenced by distinct loci, none of which overlapped between drugs. These results suggest that susceptibility to chemotherapy-induced hematotoxicity is influenced by different genes for different chemotherapy drugs.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , , , , , et al. High-resolution genetic mapping in the diversity outbred mouse population identifies Apobec1 as a candidate gene for atherosclerosis. G3 (Bethesda) 2014; 4: 2353–2363.

  2. 2.

    , , , , , et al. High-throughput pharmacogenetics identifies SLCO1A2 polymorphisms as candidates to elucidate the risk of febrile neutropenia in the breast cancer RAPP-01 trial. Breast Cancer Res Treat 2015; 153: 383–389.

  3. 3.

    , , , , , et al. Identification of PLOD2 as telopeptide lysyl hydroxylase, an important enzyme in fibrosis. J Biol Chem 2003; 278: 40967–40972.

  4. 4.

    , , , , , et al. Estimating podocyte number and density using a single histologic section. J Am Soc Nephrol 2014; 25: 1118–1129.

  5. 5.

    , , , , , et al. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA 1997; 94: 4028–4033.

  6. 6.

    , , , , , et al. Genome-wide association study of chemotherapeutic agent-induced severe neutropenia/leucopenia for patients in Biobank Japan. Cancer Sci 2013; 104: 1074–1082.

  7. 7.

    , , , , , et al. Identifying genes that mediate anthracyline toxicity in immune cells. Front Pharmacol 2015; 6: 62.

  8. 8.

    , , , . Using Drosophila melanogaster to identify chemotherapy toxicity genes. Genetics 2014; 198: 31–43.

  9. 9.

    , , , , , et al. Quantitative trait locus mapping methods for diversity outbred mice. G3 (Bethesda) 2014; 4: 1623–1633.

  10. 10.

    , , , , , et al. High-resolution genetic mapping using the Mouse Diversity outbred population. Genetics 2012; 190: 437–447.

  11. 11.

    , , , , , et al. Diversity outbred mice identify population-based exposure thresholds and genetic factors that influence benzene-induced genotoxicity. Environ Health Perspect 2015; 123: 237–245.

  12. 12.

    , . Comparison of carbon dioxide/air mixture and nitrogen/air mixture for the euthanasia of rodents: design of a system for inhalation euthanasia. Anim Technol 1984; 35: 93–99.

  13. 13.

    , , , , , et al. Aging Research Using Mouse Models. Curr Protoc Mouse Biol 2015; 5: 95–133.

  14. 14.

    , , , . Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin. Clin Cancer Res 2005; 11: 3915–3924.

  15. 15.

    , , , , . A mouse-based strategy for cyclophosphamide pharmacogenomic discovery. J Appl Physiol (1985) 2003; 95: 1352–1360.

  16. 16.

    Collaborative Cross Consortium. The genome architecture of the Collaborative Cross mouse genetic reference population. Genetics 2012; 190: 389–401.

  17. 17.

    , , , , , et al. Mouse genomic variation and its effect on phenotypes and gene regulation. Nature 2011; 477: 289–294.

  18. 18.

    , , , , , et al. Sequence-based characterization of structural variation in the mouse genome. Nature 2011; 477: 326–329.

  19. 19.

    , . Empirical threshold values for quantitative trait mapping. Genetics 1994; 138: 963–971.

  20. 20.

    , , . A pronounced evolutionary shift of the pseudoautosomal region boundary in house mice. Mamm Genome 2012; 23: 454–466.

  21. 21.

    , , , , , et al. Genome-wide association study of chemotherapeutic agent-induced severe neutropenia/leucopenia for patients in Biobank Japan. Cancer Sci 2013; 104: 1074–1082.

  22. 22.

    , , , . Pathways of cholesterol homeostasis in mouse retina responsive to dietary and pharmacologic treatments. J Lipid Res 2015; 56: 81–97.

  23. 23.

    , , , , , et al. Pharmacogenetic discovery in CALGB (Alliance) 90401 and mechanistic validation of a VAC14 polymorphism that increases risk of docetaxel-induced neuropathy. Clin Cancer Res 2016; 22: 4890–4900.

  24. 24.

    , , , , . Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 1984; 226: 466–468.

  25. 25.

    , . DNA damage and mutagenesis induced by nitrogen mustards. Mutat Res 1994; 318: 205–226.

  26. 26.

    , . Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst 1991; 83: 288–291.

  27. 27.

    , , . Promotion of microtubule assembly in vitro by taxol. Nature 1979; 277: 665–667.

  28. 28.

    , , , , . Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004; 56: 185–229.

  29. 29.

    . An overview of cyclophosphamide development and clinical applications. Curr Pharm Des 1999; 5: 555–560.

  30. 30.

    , . Pharmacological bone marrow purging in autologous transplantation: focus on the cyclophosphamide derivatives. Crit Rev Oncol Hematol 1993; 14: 41–60.

  31. 31.

    , , , , , . Dose intensity and toxicity associated with Taxotere formulation: a retrospective study in a population of breast cancer patients treated with docetaxel as an adjuvant or neoadjuvant chemotherapy. Anticancer Drugs 2015; 26: 984–989.

  32. 32.

    , , , , , et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2006; 24: 2019–2027.

  33. 33.

    , , . Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 2004; 100: 228–237.

  34. 34.

    , , , . Sex-specific effects of weight-affecting gene variants in a life course perspective—The HUNT Study, Norway. Int J Obes 2013; 37: 1221–1229.

  35. 35.

    , , , , , . Neutropenia induced in outbred mice by a simplified low-dose cyclophosphamide regimen: characterization and applicability to diverse experimental models of infectious diseases. BMC Infect Dis 2006; 6: 55.

  36. 36.

    , , . Role of liposomal anthracyclines in breast cancer. Ann Oncol 2007; 18 (Suppl 6): vi70–vi73.

  37. 37.

    , . Pharmacokinetics and pharmacodynamics of pegfilgrastim. Clin Pharmacokinet 2011; 50: 295–306.

  38. 38.

    , , . Successful treatment of thrombocytopenia due to marrow metastases of breast cancer with weekly docetaxel. J Natl Cancer Inst 2003; 95: 831–832.

  39. 39.

    , , , , , et al. Platelets increase the proliferation of ovarian cancer cells. Blood 2012; 120: 4869–4872.

  40. 40.

    , , . Comparative analysis and visualization of multiple collinear genomes. BMC Bioinformatics 2012; 13 (Suppl 3): S13.

  41. 41.

    , , , , , et al. Defining the consequences of genetic variation on a proteome-wide scale. Nature 2016; 534: 500–505.

  42. 42.

    , , , , , et al. The Comparative Toxicogenomics Database's 10th year anniversary: update 2015. Nucleic Acids Res 2015; 43 (Database issue): D914–D920.

  43. 43.

    , , , , , . Sorcin, a calcium binding protein involved in the multidrug resistance mechanisms in cancer cells. Molecules 2014; 19: 13976–13989.

  44. 44.

    , , , , , et al. Inhibition of sorcin reverses multidrug resistance of K562/A02 cells and MCF-7/A02 cells via regulating apoptosis-related proteins. Cancer Chemother Pharmacol 2013; 72: 789–798.

  45. 45.

    , , , , , et al. Comparative proteomics analysis of differential proteins in respond to doxorubicin resistance in myelogenous leukemia cell lines. Proteome Sci 2015; 13: 1.

  46. 46.

    , , , , , et al. Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo. J Hepatol 2005; 42: 736–743.

  47. 47.

    . Mechanisms of cancer drug resistance. Annu Rev Med 2002; 53: 615–627.

  48. 48.

    , , , , . Expression of P-glycoprotein (ABCB1) and Mrp1 (ABCC1) in adult rat brain: focus on astrocytes. Brain Res 2004; 1021: 32–40.

  49. 49.

    , , , , , et al. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 1993; 75: 451–462.

  50. 50.

    , Immunological Genome Project Consortium. The Immunological Genome Project: networks of gene expression in immune cells. Nat Immunol 2008; 9: 1091–1094.

  51. 51.

    , , , , , et al. Gene Expression Commons: an open platform for absolute gene expression profiling. PLoS ONE 2012; 7: e40321.

  52. 52.

    , , , , , et al. Alteration of genomic responses to doxorubicin and prevention of MDR in breast cancer cells by a polymer excipient: pluronic P85. Mol Pharm 2006; 3: 113–123.

  53. 53.

    , , , , , et al. Gene expression and amplification in breast carcinoma cells with intrinsic and acquired doxorubicin resistance. Oncogene 2001; 20: 1300–1306.

  54. 54.

    , , , , , et al. Abcb4 acts as multixenobiotic transporter and active barrier against chemical uptake in zebrafish (Danio rerio) embryos. BMC Biol 2013; 11: 69.

  55. 55.

    , , , , , et al. Simultaneous determination of cyclophosphamide, ifosfamide, doxorubicin, epirubicin and daunorubicin in human urine using high-performance liquid chromatography/electrospray ionization tandem mass spectrometry: bioanalytical method validation. Rapid Commun Mass Spectrom 2008; 22: 2645–2659.

  56. 56.

    , , , , , . Simultaneous determination of four anthracyclines and three metabolites in human serum by liquid chromatography-electrospray mass spectrometry. J Chromatogr B Biomed Sci Appl 2000; 738: 281–291.

  57. 57.

    , , , , , et al. Relationship between ABCB1 gene polymorphisms and severe neutropenia in patients with breast cancer treated with doxorubicin/cyclophosphamide chemotherapy. Drug Metab Pharmacokinet 2015; 30: 149–153.

  58. 58.

    , , , , , et al. Abcb4 acts as multixenobiotic transporter and active barrier against chemical uptake in zebrafish (Danio rerio) embryos. BMC Biol 2013; 11: 69.

  59. 59.

    , , , , , et al. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol 2012; 30: 1422–1428.

  60. 60.

    , , , , , et al. Proteolytic degradation of topoisomerase II (Top2) enables the processing of Top2.DNA and Top2.RNA covalent complexes by tyrosyl-DNA-phosphodiesterase 2 (TDP2). J Biol Chem 2014; 289: 17960–17969.

  61. 61.

    , , , , , . Tyrosyl-DNA-phosphodiesterases (TDP1 and TDP2). DNA Repair 2014; 19: 114–129.

  62. 62.

    . Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer 2009; 9: 338–350.

  63. 63.

    , . The first 30 years of p53: growing ever more complex. Nat Rev Cancer 2009; 9: 749–758.

  64. 64.

    , . Astaxanthin intervention ameliorates cyclophosphamide-induced oxidative stress, DNA damage and early hepatocarcinogenesis in rat: role of Nrf2, p53, p38 and phase-II enzymes. Mutat Res 2010; 696: 69–80.

  65. 65.

    , , , . Activation of P53 in HepG2 cells as surrogate to detect mutagens and promutagens in vitro. Toxicol Lett 2010; 198: 272–281.

  66. 66.

    , , , , , et al. Tumor formation and inactivation of RIZ1, an Rb-binding member of a nuclear protein-methyltransferase superfamily. Genes Dev 2001; 15: 2250–2262.

  67. 67.

    , , , , , . KazrinE is a desmosome-associated liprin that colocalises with acetylated microtubules. J Cell Sci 2009; 122 (Pt 22): 4035–4041.

  68. 68.

    , , , , , et al. Caspase-9 is required for normal hematopoietic development and protection from alkylator-induced DNA damage in mice. Blood 2014; 124: 3887–3895.

  69. 69.

    , , , . Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells. Int J Cancer 2005; 115: 484–492.

  70. 70.

    , , . Kif1B interacts with KBP to promote axon elongation by localizing a microtubule regulator to growth cones. J Neurosci 2016; 36: 7014–7026.

  71. 71.

    , , , , , et al. Polymorphisms in the ABCB1 gene and effect on outcome and toxicity in childhood acute lymphoblastic leukemia. Pharmacogenomics J 2015; 15: 372–379.

  72. 72.

    , , , , , et al. Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 2014; 14: 241–247.

  73. 73.

    , . Presentation and management of docetaxel-related adverse effects in patients with breast cancer. Cancer Manag Res 2014; 6: 253–259.

  74. 74.

    , , , , . Controlling the false discovery rate in behavior genetics research. Behav Brain Res 2001; 125: 279–284.

  75. 75.

    , , . Drug focus: pharmacogenetic studies related to cyclophosphamide-based therapy. Pharmacogenomics 2009; 10: 1897–1903.

  76. 76.

    , , , , . Role of O6-alkylguanine-DNA alkyltransferase in protecting against cyclophosphamide-induced toxicity and mutagenicity. Cancer Res 1999; 59: 3059–3063.

  77. 77.

    , , , , , . Taxane pathway. Pharmacogenet Genomics 2009; 19: 979–983.

  78. 78.

    , , , , , et al. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics 2011; 21: 440–446.

  79. 79.

    , , , , , et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther 2012; 92: 414–417.

Download references

Acknowledgements

This work was funded by the National Cancer Institute grant number RC1 CA14550402. We thank Annika Bohner for her excellent technical assistance and Sara Cassidy for technical editing.

Author information

Affiliations

  1. The Jackson Laboratory, Bar Harbor, ME, USA

    • D M Gatti
    • , N C Goodwin
    •  & G A Churchill
  2. Saarland University Medical Center, Homburg, Germany

    • S N Weber
    •  & F Lammert

Authors

  1. Search for D M Gatti in:

  2. Search for S N Weber in:

  3. Search for N C Goodwin in:

  4. Search for F Lammert in:

  5. Search for G A Churchill in:

Competing interests

DMG and GAC are employed by The Jackson Laboratory, which sells Diversity Outbred mice.

Corresponding author

Correspondence to G A Churchill.

Supplementary information

About this article

Publication history

Received

Revised

Accepted

Published

DOI

https://doi.org/10.1038/tpj.2017.23

Supplementary Information accompanies the paper on the The Pharmacogenomics Journal website (http://www.nature.com/tpj)

Further reading